Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Emibetuzumab |
Trade Name | |
Synonyms | LY2875358 |
Drug Descriptions |
Emibetuzumab (LY2875358) is MET-targeted antibody, which inhibits binding of the MET ligand HGF and promotes internalization and downregulation of MET, resulting in decreased HGF-dependent and HGF-independent signaling and potentially leading to decreased growth of MET-expressing tumors (PMID: 27803065, PMID: 25231402, PMID: 31622732). |
DrugClasses | MET Antibody 31 MET Inhibitor 59 |
CAS Registry Number | 1365287-97-3 |
NCIT ID | C95732 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Emibetuzumab | Emibetuzumab | 0 | 2 |
Emibetuzumab + Erlotinib | Emibetuzumab Erlotinib | 0 | 2 |
Emibetuzumab + Ramucirumab | Emibetuzumab Ramucirumab | 0 | 1 |
Emibetuzumab + Trametinib | Emibetuzumab Trametinib | 0 | 1 |